Cargando…

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography

Aims: Profiling of lipoproteins can predict risk of cardiovascular disease; gel permeation high-performance liquid chromatography (HPLC) improves prediction accuracy by providing detailed data for specific lipoprotein subclasses. This study applied HPLC to examine the effects of evolocumab, which ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Daisaku, Kiyosue, Arihiro, Hirayama, Atsushi, Shimauchi, Junichiro, López, J. Antonio G., Miyawaki, Kazumasa, Yamashita, Shizuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803834/ https://www.ncbi.nlm.nih.gov/pubmed/32435010 http://dx.doi.org/10.5551/jat.54353

Ejemplares similares

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial
por: Koba, Shinji, et al.
Publicado: (2020)

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

12-Week Effectiveness and Safety of Low-Density Lipoprotein Cholesterol-Lowering Therapy by Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition in Patients With Familial Hypercholesterolemia and Hypercholesterolemia　― Data From a Real-World Observational Study of Evolocumab in Japan ―
por: Yokote, Koutaro, et al.
Publicado: (2019)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

New Horizons for Probucol, an Old, Mysterious Drug
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Relation of Serum Lipoprotein(a) Levels to Lipoprotein and Apolipoprotein Profiles and Atherosclerotic Diseases in Japanese Patients with Heterozygous Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Naito, Ryo, et al.
Publicado: (2022)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab
por: Desai, Nihar R., et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Development of internal standard for lipoprotein subclass analysis using dual detection gel-permeation high-performance liquid chromatography system
por: Ogino, Mei, et al.
Publicado: (2022)

Effect of Early Initiation of Evolocumab on Lipoprotein(a) in Patients with Acute Myocardial Infarction: Sub-Analysis of a Randomized Controlled Trial
por: Okada, Tomoaki, et al.
Publicado: (2022)

Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Acute Effect of Evolocumab on Lipoprotein(a) Level and Inflammation in Patients with Coronary Artery Disease
por: Choi, Seung Woo, et al.
Publicado: (2022)

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
por: Toth, Peter P., et al.
Publicado: (2020)

Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein
por: Okada, Takeshi, et al.
Publicado: (2021)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Analysis of lipoprotein profiles of healthy cats by gel-permeation high-performance liquid chromatography
por: MIZUTANI, Hisashi, et al.
Publicado: (2016)

Effects of Evolocumab on Cardiovascular Events
por: Mikhail, Nasser
Publicado: (2017)

Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
por: Hu, Miao, et al.
Publicado: (2015)

Particle number analysis of lipoprotein subclasses by gel permeation HPLC in patients with cholesteryl ester transfer protein deficiency
por: Okada, Takeshi, et al.
Publicado: (2018)

Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
por: Cheng, Cheng, et al.
Publicado: (2016)

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
por: Masuda, Daisaku, et al.
Publicado: (2018)

Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography
por: Hirowatari, Yuji, et al.
Publicado: (2019)

Retargeting the management of hypercholesterolemia – focus on evolocumab
por: Colletti, Alessandro, et al.
Publicado: (2016)

High performance liquid chromatography
por: Lindsay, Sandie
Publicado: (1992)

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis of Individual Participant Data From Double‐Blind and Open‐Label Extension Studies
por: Daviglus, Martha L., et al.
Publicado: (2020)

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients
por: Kurozumi, Akira, et al.
Publicado: (2017)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
por: Cicero, Arrigo FG, et al.
Publicado: (2015)

Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
por: Lee, Timothy, et al.
Publicado: (2019)

Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021)

Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab
por: Tanaka, Akihito, et al.
Publicado: (2017)

Practical high-performance liquid chromatography /
por: Meyer, Veronika
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_oillbera2fao04du96u4evhdnm